What are the prospects for early diagnosis, CRISPR gene-editing, and CAR T-cell therapies in myeloma?

What does the new cancer research mean for patients? IMF Chairman Dr. Brian G.M. Durie sees a fresh take on MGUS, the curative potential of cloning, and questions on the value of early diagnosis.

ASH 2017: Separating Hype from Hope About CAR T-Cell Therapy

At the 2017 Annual Meeting of the American Society of Hematology (ASH) in Atlanta (December 9th -12th), 981 abstracts dealt with myeloma-related topics. Among all of these— some of which were discussed on the IMWG Conference Series broadcast on Monday, December 11th, and which I will discuss in more detail during the ASH Highlights Teleconference on January 11th-- the “big buzz” was about the CAR T-cell (chimeric antigen receptors) clinical trial results.

University of California girds to combat cancer, a closer look at CAR-T cell therapy, and medical tourism to China—a wave of the future?

With new drug approvals and expanded indications for new myeloma drugs at an all-time high, there is a sense of optimism in the myeloma community. Yet, even as patients experience longer survival, myeloma remains very sneaky. The disease can evolve into resistant relapse phases, demanding new therapy.

With the Solar Eclipse, Millions Understand That Science is Not Fake News

At 10:21 a.m. Los Angeles time on Monday, August 21st, the moon covered 62% of the sun. In Oregon and across the US, there were 2.3 minutes of total darkness. Scientists had been informing everyone about this upcoming event for many years, and it occurred exactly on schedule: a natural event.

Positive Butterfly News, Immune Tweaking with CRISPR, and Looking to the Future in China

As I reported in a previous blog, not only does the herbicide Roundup cause lymphomas and myeloma, its widespread use on GMO (genetically modified organism) crops has decimated milkweed, an herbaceous perennial and the essential food for monarch butterflies. Since 1990, about 970 million monarchs have vanished.

Pages